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Purpose of the study
The efficacy of raltegravir (RAL) in salvage regimens
without protease inhibitors( P I )h a sn o tb e e ne v a l u a t e d
in randomized trials, and information about its efficacy
and reasons for its initiation in cohort studies has
received scant attention. In some particular scenarios
physicians may be forced to use RAL without PI due to
advanced protease resistance, toxicity or patient refusal.
Methods
Systematic multicenter search of databases in Univer-
sity-affiliated hospitals in Spain to identify all pre-treated
patients with limited options due to resistance or intol-
erance to multiple antiretrovirals, starting a regimen
including raltegravir and not a PI for any given reason,
with a baseline plasma HIV-1 viral load (VL) >500
copies/mL. Primary endpoint: proportion achieving a
VL<50 c/mL at 48 weeks.
Results
We identified 55 patients, 69% male, with a median age of
45,8 y., 40% IVDU, 45% with chronic hepatitis C, 40% in
stage CDC C. Fourteen (25%) were diagnosed of dyslipide-
mia. 19/20 (95%) patients with results available had a
CCR5 tropism. The main reasons for initiating a regimen
with RAL and without PI were advanced protease resis-
tance (44%), toxicity (15%), pharmacokinetic interactions
(11%), and patient refusal (7%). The most frequently used
drugs on board were tenofovir in 43 (78%) patients, mara-
viroc in 16 (29%) patients, and etravirine in 11 (20%).
Eight (14%) patients did not use any nucleoside analogue,
all of them due to complete resistance or toxicity. At 48
weeks, 66% of them had an HIV-1 VL < 50 c/mL. There
was a significant increase in the median CD4 cell count
from 257 cells/<micro>L at baseline to 415 cells/µL at 48
weeks (p=0.01), with only 19% of patients remaining with
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documented in 4 (7%) patients. There were no unexpected
adverse events related to RAL when used without PI.
Conclusions
Salvage regimens including RAL but not PI may be used
in selected patients mainly due to advanced protease
resistance, toxicity, pharmacokinetic interactions or
patient refusal to PI. The efficacy of raltegravir when
used with a background regimen without a protease
inhibitor is high, but the inclusion of 2 further active
drugs must be strongly pursued. This cohort analysis
supports further study of RAL with novel combinations
in this difficult-to-treat population.
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